Skip to content
BALCAO · SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH · SMALL CAP

Vitaspring Biomedical Co. Ltd. VSBC

10 fiscal years on record · USD · FY2025 reported · SEC filings only
$0
$-415,368

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 0.00
Revenue, FY2025 · full 10-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.0 · Net income -0.4
2M4M-2M-3M
2016201920222025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2021 · Operating 20.1% · Net 16.2%
50%100%150%
201620202025
ROE
FY2021 · ROE 108.7%
200%400%
201620202025
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.
Return on capital employedNot applicable: capital employed was zero or negative in this period, so return on capital employed has no meaning.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $
FY2022 · FCF -77556.0
-150000-300000
201620202025
Net buybacks $ Dividends $
FY2017 · Dividends · · Net buybacks 100.0
50100
2017

Total assetsUSD 14,676.00
EquityUSD -4.4M
CashUSD 2,084.00
Current ratio0.00×

Equity funds -30189% of total assets.

The 10-year record

10 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
VSBC, 10-year financial record
Metric 2025202420232022202120202019201820172016
Revenue $B0.00.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.00.00.00.0−0.0−0.0◌
EBITDA $B−0.0−0.0−0.0−0.00.00.00.0−0.0−0.0◌
Income tax $B0.00.00.0−0.00.00.00.00.0◌◌
Net income $B−0.0−0.0−0.0−0.00.00.00.0−0.0−0.0−0.0
Free cash flow $B◌◌◌−0.0−0.0◌◌◌◌◌
EPS, diluted $0.000.00−0.01−0.020.000.000.000.000.000.00
Dividend / sh $◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend——————————
ROE %————108.7441.4———−1.5
Shares out B0.210.21◌0.150.120.210.010.01◌◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 6 failures in 42 reconciliationsAUDITED

Reconciled in 7 of the 10 fiscal years we could check. 18 checks were skipped: the balance sheet is not tagged before 2016. Nine checks were skipped: EPS is not tagged before 2016. Nine checks were skipped: revenue is not tagged before 2016.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency6 failures
ActivityServices-Commercial Physical & Biological Research
Listed onOTC market
Incorporated inNevada
Fiscal year endsJanuary 31
SEC categorysmaller reporting company
Data on record since2016

Share this section

Download image